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Characteristic N (%)
Sex
Male 13 (32)
Female 6 (68)
Lymphoma Type
Hodgkin’s 7 (37)
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more affordable cladribine (Clad) can supplant Clo with or
without epigenetic modulators, using panobinostat (Pano)
and 5-aza-20-deoxycytidine (DAC) as prototype represen-
tatives of such agents. Both [Clad+Flu+Bu] and [Clo+-
Flu+Bu] combinations showed synergistic cytotoxicity in
KBM3/Bu2506, HL60 and OCI-AML3 cell lines with 60%-80%
inhibition of proliferation. Drug exposure resulted in acti-
vation of the ATM pathway, increase in histone modi-
ﬁcations with corresponding decreased levels of HDAC3,
HDAC4, HDAC5 and SirT7, decrease in mitochondrial
membrane potential, activation of apoptosis and stress
signaling pathways, and down-regulation of the pro-sur-
vival AKT pathway. Similarly, these drug combinations
activated DNA-damage response and apoptosis in primary
cell samples from AML patients. At lower concentrations of
Clad/Clo, Flu and Bu, inclusion of Pano and DAC yielded a
signiﬁcant increase in histone modiﬁcations and DNA
demethylations, resulting in further enhanced cell killing.
Inclusion of Pano decreased histone deacetylases and
demethylases. The presence of DAC decreased the level of
DNA methyl transferase 1 (DNMT1), which consequently
increased the levels of cell-cycle checkpoint proteins
such as P16/INK4a, P15/INK4b and P21/Waf1/Cip1. We
also demonstrated the DNA demethylating activity of
Clad and Clo, which may be augmented by DAC activity
and caused degradation of b-catenin in cells exposed to
[Clad/Clo+Flu+Bu+DAC+Pano]. Increased demethylations of
the gene promoters for SFRP1, DKK3 and WIF1 were
observed with concomitant up-regulation of their expres-
sions; the encoded proteins are known to antagonize
the pro-survival Wnt/b-catenin pathway. The overlapping
activities of [Clad/Clo+Flu+Bu], Pano and DAC in DNA-
damage formation, histone modiﬁcations, DNA deme-
thylation and apoptosis may explain their synergism. A
proposed model for the observed drug synergism in AML
cells is shown below. Our results provide a basis for sup-
planting Clo with Clad and for including epigenetic modi-
ﬁers in the pre-HSCT conditioning regimen for myeloid
leukemia patients.NHL 7 (37)
CLL/PLL 5 (26)
Disease Status at Transplant
CR/CRU 5 (26)LYMPHOMA/MULTIPLE MYELOMA
PR 10 (53)
SD 3 (16)
PD 1 (5)
Conditioning Intensity
MA 11 (58)
NMA 8 (42)
Donor Relation
Parent 4 (21)
Child 4 (21)
Sibling 11 (58)254
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Introduction: Haploidentical transplantation with post-
transplant cyclophosphamide (PTCy) using the non-mye-
loablative (NMA) conditioning regimen with Flu/Cy/TBI
has been associated with low treatment-related mortality
(TRM) for lymphoma patients. We investigated a more
intense, melphalan-based regimen in an attempt to improve
disease control post-transplant for advanced lymphoma
patients.
Methods: All patients who received a bone marrow Hap-
loSCT at MD Anderson for high-risk lymphoma/CLL after
2009 were reviewed. Initially, patients received myeloa-
blative (MA) conditioning with ﬂudarabine and melphalan
140 mg/m2(FM140) +/- thiotepa 5-10 mg/kg. Due to con-
cerns of increased TRM, a lower intensity conditioning
regimen with melphalan 100 mg/m2 (FM100) +/- thiotepa
5 mg/kg or 2Gy TBI was adopted. Rituximabwas included for
CD20+ disease. GVHD prophylaxis consisted of tacrolimus/
MMF/PTCy, as previously described. One patient was treated
with the Flu/Cy/TBI regimen. Univariate comparisons were
done utilizing the log-rank test.
Results: Nineteen patients, with a median age of 45 years
(range 20-62) underwent HaploSCT for advanced lymphoma.
Characteristics of these patients are described in the Table.
Seventy-four percent of patients were not in remission at
transplant. Of the patients not in CR/CRU at transplant, 9/14
(64%) remain alive. Engraftment occurred in 18 patients
(95%), with one incident of primary graft failure. Best
chimerism was full donor in 16/19 (84%) of patients. Cumu-
lative incidence (CI) of grade II-IV acute GVHDwas 44% at day
100. Only 2 patients developed chronic GVHD, 1 limited, 1
extensive. After a median follow-up time of 22 months,
median OS and PFS for this group was 63% and 52%,
respectively. The 2-year CI of TRM and disease relapse were
11% and 26%. PFS at 2 years for patients receiving NMA
conditioning was 70% compared to 31% in patients receiving
MA conditioning (p¼0.29).
Conclusions: FM100 regimen appears at least as effective as
FM140 as conditioning for patients with advanced lym-
phoma receiving HaploSCT, with excellent disease control
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Background: Cyclophosphamide (Cy) is used in combination
with novel drugs for the treatment of newly diagnosed and
relapsedmultiplemyeloma (MM). In this retrospective study,
we report the University of Florida experience with Cy
maintenance therapy in patients who could not tolerate or
previously failed 1st line maintenance therapy after autolo-
gous stem cell transplantation (ASCT).
Methods: We evaluated MM patients who received in-
duction chemotherapy and ASCT from 2000 to 2010. The
patients were divided into four groups based on the main-
tenance therapy prescribed post ASCT or after ﬁrst relapse:
No maintenance (observation), interferon and/or prednisone
(I/P), immunomodulatory drugs (IMiDs; thalidomide or
lenalidomide), and Cy. Overall 32 patients received Cy for
maintenance. Cy was given as 200 mg/day orally x 10 days
every 28 days (n¼28) or IV 750 mg/m2 every 21 days (n¼4).
Progression free survival (PFS) and overall survival (OS) was
analyzed using the log-rank test. Group characteristics were
studied using descriptive statistics.
Results: 286 patients underwent ASCT; patients with less
than six months of post-ASCT follow-up (8) and those
treated with allogeneic transplant (21) were excluded. Of the
remaining 257 patients, 36 patients received tandem ASCT.
The cohort was 45.9% female with a mean age at diagnosis of
57.4 years. Eleven patients had Cy maintenance post ASCT
(Cy1) and 21 received Cy after 1st relapse and salvage
chemotherapy (Cy2). Median PFS (from ASCT) and OS (from
diagnosis) for the entire Cy group was 22.6 and 76 months,respectively. After ASCT, patients in the Cy1 group had
similar disease stage distribution but a lower rate of VGPR/CR
(18.2%) in comparison to the other groups. There was no
signiﬁcant difference in PFS or OS in the Cy1 group vs. the
IMiDs (n¼75) or the observation (n¼ 105) groups. Patients
treated with IMiDs maintenance had signiﬁcantly longer PFS
(P¼0.001) and OS (P¼0.0322) vs. observation. Cy was well
tolerated with a dose reduction necessary in one patient due
to cytopenias. A similar analysis for Cy2 showed no signiﬁ-
cant difference in PFS and OS between Cy and other main-
tenance therapies. Speciﬁcally, there was no signiﬁcant
difference in PFS (10.4 vs.17.6months, p¼0.07) and OS (mean
91.7 vs. 95.7 months, p¼0.08) of patients receiving Cy2 when
compared to the IMiDs group (n¼31). IMiDs maintenance
therapy again demonstrated superior OS in comparison to
observation (p ¼ 0.018) in the second-line setting. Cy2 was
well tolerated with dose reductions necessary in 3/21 pa-
tients (cytopenias [2] and nausea [1]); Cy was discontinued
in 4/21 due to cytopenias. One patient in Cy1 group devel-
oped hypoplastic myelodysplastic syndrome after > 3 years
on Cy.
Conclusions: Cy maintenance therapy may be an effective
and well-tolerated alternative after ASCT, particularly in the
second-line setting, and when other maintenance options
are not feasible.
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Background: Lymphoma represents the third most common
cancer under 15yrs of age and the most common cancer in
adolescents and young adults.(Hochberg/Cairo, BJH 2009)
Hodgkin Lymphoma occurs in approximately 7,500 people
per yr in the U.S. EBV infection has been suggested to be one
of several causative possibilities in its pathogenesis with
about 40% of HL being EBV-associated. Autologous T cells
directed to LMP1/2 antigens can induce durable responses in
high risk patients without signiﬁcant toxicity.(Bollard, JCO
2014) Although there have been signiﬁcantly improved
outcomes, those with progressive or relapsed disease often
require alternative strategies with limited good options.
Objectives: We intend to analyze the toxicity and overall
response rate of allogeneic HLA matched donor derived
latent membrane protein (LMP) speciﬁc-cytotoxic T cell
lymphocytes (CTLs) in children, adolescents and young
adults (CAYA) with EBV-associated refractory or relapsed
Hodgkin lymphoma (HL) following reduced intensity
